TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05803941: A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Adult Participants With Prostate Cancer

Sponsor: Novartis Pharmaceuticals · Phase: PHASE4 · Area: ONCOLOGY · Target Enrollment: 700 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$9,498,720

Rescue Site Savings

+$6,283,200

Unlock Full NCT05803941 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05803941 Rescue Dossier →